0001209191-16-096726.txt : 20160209
0001209191-16-096726.hdr.sgml : 20160209
20160209162245
ACCESSION NUMBER: 0001209191-16-096726
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160205
FILED AS OF DATE: 20160209
DATE AS OF CHANGE: 20160209
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lloyd-Smith Malcolm
CENTRAL INDEX KEY: 0001557146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 161400085
MAIL ADDRESS:
STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-02-05
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001557146
Lloyd-Smith Malcolm
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
Restricted Stock Unit
2016-02-05
5
A
0
E
7700
0.00
A
Common Stock
7700
7700
D
Stock Option
35.99
2016-02-05
5
A
0
E
36400
0.00
A
2026-02-05
Common Stock
36400
36400
D
Restricted Stock Unit
2016-02-05
5
A
0
E
20500
0.00
A
2020-02-05
Common Stock
20500
20500
D
Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2017, February 5, 2018, February 5, 2019, and February 5, 2020.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2016 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine.
/s/ Darin Lippoldt, Attorney-In-Fact
2016-02-09